IL307882A - Cyclic-N-acetylgalactosamine (GALNAC) peptide conjugates for drug delivery to liver cells - Google Patents
Cyclic-N-acetylgalactosamine (GALNAC) peptide conjugates for drug delivery to liver cellsInfo
- Publication number
- IL307882A IL307882A IL307882A IL30788223A IL307882A IL 307882 A IL307882 A IL 307882A IL 307882 A IL307882 A IL 307882A IL 30788223 A IL30788223 A IL 30788223A IL 307882 A IL307882 A IL 307882A
- Authority
- IL
- Israel
- Prior art keywords
- galnac
- acetylgalactosamine
- conjugates
- drug delivery
- cyclic peptide
- Prior art date
Links
- 125000004122 cyclic group Chemical group 0.000 title 1
- 238000012377 drug delivery Methods 0.000 title 1
- 210000005229 liver cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021089305 | 2021-04-23 | ||
| PCT/CN2022/088117 WO2022222986A1 (en) | 2021-04-23 | 2022-04-21 | Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307882A true IL307882A (en) | 2023-12-01 |
Family
ID=83723528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307882A IL307882A (en) | 2021-04-23 | 2022-04-21 | Cyclic-N-acetylgalactosamine (GALNAC) peptide conjugates for drug delivery to liver cells |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240218023A1 (https=) |
| EP (1) | EP4326744A1 (https=) |
| JP (1) | JP2024516613A (https=) |
| KR (1) | KR20240044385A (https=) |
| CN (1) | CN117529490A (https=) |
| AU (1) | AU2022261265A1 (https=) |
| IL (1) | IL307882A (https=) |
| WO (1) | WO2022222986A1 (https=) |
| ZA (1) | ZA202309922B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024117938A1 (ru) * | 2022-11-30 | 2024-06-06 | Общество с ограниченной ответственностью "СИСТЕМА-БИОТЕХ" | Способы получения биоконъюгатов для печень-специфической направленной модуляции протеома |
| WO2024152775A1 (zh) * | 2023-01-17 | 2024-07-25 | 云合智药（苏州）生物科技有限公司 | 缀合物、配体单元及其用途 |
| TW202517784A (zh) * | 2023-07-14 | 2025-05-01 | 大陸商云合智藥（蘇州）生物科技有限公司 | 用於抑制己酮糖激酶表達的ＲＮＡｉ劑及其應用 |
| CN120040554B (zh) * | 2025-04-25 | 2025-07-18 | 云合智药（苏州）生物科技有限公司 | 环肽类肝靶向化合物、药物组合物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501930B2 (en) * | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| US11987647B2 (en) * | 2018-05-09 | 2024-05-21 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
-
2022
- 2022-04-21 US US18/556,040 patent/US20240218023A1/en active Pending
- 2022-04-21 EP EP22791092.4A patent/EP4326744A1/en active Pending
- 2022-04-21 AU AU2022261265A patent/AU2022261265A1/en active Pending
- 2022-04-21 IL IL307882A patent/IL307882A/en unknown
- 2022-04-21 CN CN202280043909.8A patent/CN117529490A/zh active Pending
- 2022-04-21 JP JP2023564508A patent/JP2024516613A/ja active Pending
- 2022-04-21 KR KR1020237040193A patent/KR20240044385A/ko active Pending
- 2022-04-21 WO PCT/CN2022/088117 patent/WO2022222986A1/en not_active Ceased
-
2023
- 2023-10-24 ZA ZA2023/09922A patent/ZA202309922B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117529490A (zh) | 2024-02-06 |
| JP2024516613A (ja) | 2024-04-16 |
| ZA202309922B (en) | 2025-05-28 |
| EP4326744A1 (en) | 2024-02-28 |
| US20240218023A1 (en) | 2024-07-04 |
| AU2022261265A1 (en) | 2023-11-09 |
| AU2022261265A9 (en) | 2023-11-16 |
| WO2022222986A1 (en) | 2022-10-27 |
| KR20240044385A (ko) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL307882A (en) | Cyclic-N-acetylgalactosamine (GALNAC) peptide conjugates for drug delivery to liver cells | |
| MX2009011165A (es) | Formulaciones farmaceuticas que contienen derivados del acido lipoico. | |
| PH12015501422B1 (en) | Hydrophilic self-immolative linkers and conjugates thereof | |
| NZ758050A (en) | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics | |
| CO6501124A2 (es) | Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas | |
| EP2747563A4 (en) | COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS | |
| BR112016028835A2 (pt) | derivados de auristatina e conjugados dos mesmos | |
| EA201390381A1 (ru) | Триазиноксадиазолы | |
| EP2629786A4 (en) | COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS | |
| EP2401011A4 (en) | MEDICAL MODULE FOR ACTIVE SUBSTANCE SPEN | |
| MX358399B (es) | Conjugados de un resto de interleucina-2 y un polímero. | |
| EP2405967A4 (en) | IMPLANTABLE DEVICE FOR LONG-TERM ADMINISTRATION OF MEDICINAL PRODUCTS | |
| EP2381773A4 (en) | COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS | |
| MX2009013835A (es) | Forma de dosis estabilizada de picoplatino. | |
| BR112013004440A2 (pt) | método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral | |
| NZ623294A (en) | Stabilized alpha-galactosidase and uses thereof | |
| MY194495A (en) | Compositions and methods for transmucosal absorption | |
| WO2013067199A3 (en) | Subcutaneous delivery of polymer conjugates of therapeutic agents | |
| PH12013502204A1 (en) | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists | |
| IN2014DN00277A (https=) | ||
| TR200908237A2 (tr) | Kalsiyum ve D vitamini içeren farmasötik bileşimler. | |
| AU2012253610A8 (en) | Compositions and methods for treating cancer | |
| ZA201200185B (en) | Cell protection in dialysis patients by administration of a creatine compound | |
| MX2013000729A (es) | Composiciones ciclopolisacárido anionico-catiónico y bendamustina. | |
| IL317870A (en) | Biopolymer formulations for drug delivery |